Simpson Thacher Represents Underwriters in HK$2.51 Billion Hong Kong IPO and Rule 144A/Regulation S Offering of MicroPort CardioFlow
02.04.21
This is only gets display when printing
The Firm represented the underwriters in the initial public offering and Rule 144A and Regulation S offering by MicroPort CardioFlow Medtech Corporation (“MicroPort CardioFlow”). MicroPort CardioFlow offered an aggregate of 205,620,000 shares prior to the exercise of the underwriters’ overallotment option. The base offering size was HK$2.51 billion (approximately US$321.6 million). The shares of MicroPort CardioFlow are listed on the Main Board of the Hong Kong Stock Exchange. J.P. Morgan, Citi and CICC acted as the joint sponsors, joint global coordinators, joint bookrunners and joint lead managers.
MicroPort CardioFlow is a medical device company in China focusing on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases.
The Simpson Thacher team for the transaction included Celia Lam, Yi Gao, Michelle Leung, Quan Zhou and Christy Li (Capital Markets).